AS1411-functionalized delivery nanosystems for targeted cancer therapy

Pooria Safarzadeh Kozani1, Pouya Safarzadeh Kozani2,3, Mohammad Tariq Malik4,5

  • 1Carlos Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran 14115/111, Iran.

Exploration of Medicine
|November 1, 2021
PubMed

Insights

Nucleolin (NCL) is a cancer target, and the AS1411 aptamer binds it effectively. AS1411-functionalized nanosystems offer targeted cancer therapy by delivering agents specifically to tumor cells.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Nucleolin (NCL) is a key protein involved in cell proliferation, survival, and growth.
  • Overexpression and dysregulation of NCL are linked to various cancers, making it a promising therapeutic target.

Purpose of the Study:

  • To review advances in cancer therapy targeting Nucleolin (NCL) using AS1411-functionalized delivery nanosystems.
  • To explore the selective delivery of therapeutic agents to tumor cells via NCL targeting.

Main Methods:

  • AS1411, a DNA aptamer with high affinity for NCL, was utilized.
  • Nanosystems were functionalized with AS1411 for targeted delivery.
  • The review explores therapeutic payload delivery to tumor cells.

Main Results:

  • AS1411 demonstrates high affinity and specificity for NCL.
  • AS1411 induces growth inhibition in various tumor cells.
  • AS1411-functionalized nanosystems enable selective targeting of tumor cells.

Conclusions:

  • AS1411 is a potent NCL-targeting agent for cancer therapy.
  • Functionalized nanosystems enhance targeted delivery of therapeutics.
  • This approach holds promise for selective cancer treatment.